Anne‐Lise Børresen

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

Turid Aas, Anne‐Lise Børresen, Stephanie Geisler et al. · Nature Medicine · 1996 · 737 citations

Breast Oncology, Breast Cancer Patients, Medicine +9

Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology

Vidar M. Steen, Ole A. Andreassen, Ann K. Daly et al. · Pharmacogenetics · 1995 · 243 citations

SERUM-HIGH-DENSITY-LIPOPROTEIN AND ATHEROSCLEROTIC HEART-DISEASE

Kåre Berg, Anne‐Lise Børresen, Gösta Dahlén · The Lancet · 1976 · 222 citations

Metabolic Syndrome, Cardiovascular Disease, Atherosclerosis +5

<i>TP53</i> mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains

Anne‐Lise Børresen, Tone Ikdahl Andersen, Jórunn E. Eyfjörd et al. · Genes Chromosomes and Cancer · 1995 · 181 citations

Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection

Eivind Hovig, Birgitte Smith‐Sørensen, Anton Brögger et al. · Mutation Research Letters · 1991 · 132 citations

Genetic Analysis, Genetic Testing, Mutation-based Testing +9